NovaScan Awarded $3.7 Million CPRIT Grant to Advance MarginScan™ for Breast Cancer Surgery | NovaScan
Summary
NovaScan secured a $3.7 million non-dilutive CPRIT grant to advance MarginScan for breast cancer surgery. The funding will support clinical work and deployment of the real-time surgical margin assessment platform in breast-conserving procedures. MarginScan uses biospectral impedance and AI analytics to help surgeons detect residual cancer before closing an incision. NovaScan also highlighted commercial traction through a letter of intent with Epredia as its primary U.S. distribution partner. The company plans to expand the platform across multiple cancer types and improve surgical outcomes.
Funding
Amount
$3.7M
Total raised
Date
November 21, 2025
Announcement date
Investors
Epredia, PHC Holdings, State of Texas
Lead investors
Company
https://novascaninc.com
Funded company
Classifications
industries
HealthTech
applications
Web and Content Management
AskAI Classifications
Labels
No AI classifications detected